NCT06846528

A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants

An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.

Detailed description

This study will be an open-label, fixed sequence, Drug-Drug Interaction (DDI) study consisting of 3 periods. The study will comprise: * A screening period of maximum 28 days * Period 1 * Period 2 * Period 3 * A Follow-up Visit 7 to 14 days after the last PK sample has been collected.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	AZD2389	AZD2389 is administered orally
DRUG	Itraconazole	Itraconazole is administered orally

Timeline

• Start date: 2025-02-26
• Primary completion: 2025-04-23
• Completion: 2025-04-23
• First posted: 2025-02-26
• Last updated: 2025-04-29

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study